Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading VRXA daily closes…
Loading price history…
Pipeline assets
VX-A901
Phase 1 · ActiveModality: Antibody
Aliases formerly FLYSIN
Target FLT3
Partnerships Acquired via Synimmune acquisition (formerly FLYSYN)
Indications
Acute myeloid leukemia(Phase 1)
Status note Anti-tumor antibody acquired via the Synimmune GmbH acquisition (Dec 29, 2023); successfully completed a Phase I clinical trial for AML.
Per-asset detail extracted from the 20-F filed 2026-06-16. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.